Prevalence
Causes
Clinical
features
Investigations
Therapy
Prevention
Prognosis
|  |  | | Prevention |
Contrast medium nephrotoxicity
Give high-risk patients pre- and post-contrast
- 0.45% saline (1 mg/kg/hr for 12 hours) c

- acetylcysteine 600 mg orally twice daily a

Why?
- Patients with chronic renal insufficiency who received
acetylcysteine and saline compared with placebo and saline
are less likely to develop an acute reduction in renal
function, and have a smaller change in
serum creatinine levels (on average 50 µmol less). a

Acetylcysteine reduces worsening renal function following contrast
media.
| Patient |
Treatment |
Comparison |
Outcome |
CER |
RRR (95% CI) |
NNT
(95% CI) |
chronic renal insufficiency undergoing CT contrast study a
|
acetylcysteine and saline infusion
|
placebo and saline infusion
|
acute reduction in renal function
at 2 days
|
21%
|
89% (14% to 98%)
|
5
(3 to 18)
|
|